TandemAI, a Suzhou, and Shangai, China-based provider of a computational platform to accelerate the design and optimization of drug candidates, raised $25 million in seed and pre-Series A financing.
The round was led by OrbiMed and Chengwei Capital. In conjunction with the funding, David Wang, M.D., Ph.D., Senior Managing Director and Partner at OrbiMed, will join TandemAI’s Board of Directors.
The company intends to use the funds to advance its proprietary computational platform and expansion of its wet lab operations. The company will integrate the computational platform with wet labs for biophysics, medicinal chemistry, and biology to accelerate the design and optimization of drug candidates for partners.
Round: Seed and pre-Series A
Funding Month: December 2021
Lead Investors: OrbiMed and Chengwei Capital
Company Website: https://www.tandemai.com/
Software Category: a computational platform
About the Company: Led by Jeff He, MBA, co-founder, and CEO, TandemAI is an advanced technology company dedicated to integrating proprietary AI-driven, high-performance computation with large-scale in-house wet lab operations to deliver a comprehensive drug discovery solution. The company has built its networked platform from the ground up in China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and the global scientific community. TandemAI is rapidly setting up wet labs and computing clusters in China.